Generic Name and Formulations:
Dexlansoprazole 30mg, 60mg; delayed-release caps.
Company:
Takeda Pharmaceuticals North America, Inc.
Healing of all grades of erosive esophagitis (EE). Treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). Maintenance of healing of EE and relief of heartburn.
≥18yrs: Swallow whole, or sprinkle granules on 1 tablespoon of applesauce and swallow immediately. EE healing: 60mg once daily for up to 8 weeks. Maintenance of healed EE and relief of heartburn: 30mg once daily for up to 6 months. Symptomatic GERD: 30mg once daily for 4 weeks. Moderate hepatic impairment (Child-Pugh Class B): max 30mg/day.
<18yrs: not established.
Proton pump inhibitor.
Gastric malignancy. Use lowest dose for shortest duration appropriate to condition. If diarrhea occurs that does not improve, consider C. difficile diagnosis. Increased risk of osteoporosis-related fractures of the hip, wrist or spine with long-term and multiple daily dose PPI therapy. Severe hepatic impairment. Monitor magnesium levels with long-term therapy. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concomitant atazanavir: not recommended (may decrease atazanavir levels). May alter absorption of pH-dependent drugs (eg, ketoconazole, digoxin, iron, ampicillin). Monitor warfarin. May increase tacrolimus, methotrexate levels.
Diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, flatulence; rare: hypomagnesemia (w. prolonged PPI therapy).
Formerly marketed as Kapidex.
Hepatic (CYP2C19, 3A4); 96.1–98.8% protein bound.
Renal, fecal
NO
Caps—30, 90, 1000